Aileron Therapeutics Inc (NASDAQ:ALRN) traded up 15.3% on Monday . The stock traded as high as $0.69 and last traded at $0.68, 409,099 shares were traded during trading. An increase of 56% from the average session volume of 261,514 shares. The stock had previously closed at $0.59.

Several equities analysts have weighed in on the company. Zacks Investment Research lowered Aileron Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Aileron Therapeutics in a report on Wednesday, August 7th. William Blair restated an “outperform” rating on shares of Aileron Therapeutics in a report on Monday, May 6th. Finally, ValuEngine upgraded Aileron Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $4.00.

The company has a fifty day simple moving average of $0.59 and a two-hundred day simple moving average of $1.25. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.16.

Aileron Therapeutics (NASDAQ:ALRN) last posted its earnings results on Tuesday, August 6th. The company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.03). On average, equities research analysts anticipate that Aileron Therapeutics Inc will post -1.14 EPS for the current year.

In other Aileron Therapeutics news, SVP Kathryn Gregory acquired 45,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were acquired at an average cost of $0.65 per share, for a total transaction of $29,250.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Vojo Vukovic acquired 75,000 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $0.59 per share, for a total transaction of $44,250.00. The disclosure for this purchase can be found here. Insiders own 6.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Aileron Therapeutics by 179.6% in the second quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock worth $36,000 after purchasing an additional 31,787 shares during the period. Deutsche Bank AG increased its stake in shares of Aileron Therapeutics by 432.9% in the fourth quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock worth $108,000 after purchasing an additional 104,932 shares during the period. Vanguard Group Inc. increased its stake in shares of Aileron Therapeutics by 261.6% in the second quarter. Vanguard Group Inc. now owns 333,005 shares of the company’s stock worth $240,000 after purchasing an additional 240,910 shares during the period. Finally, Jennison Associates LLC increased its stake in shares of Aileron Therapeutics by 649.6% in the first quarter. Jennison Associates LLC now owns 2,040,255 shares of the company’s stock worth $3,828,000 after purchasing an additional 1,768,073 shares during the period. Institutional investors and hedge funds own 23.05% of the company’s stock.

Aileron Therapeutics Company Profile (NASDAQ:ALRN)

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Featured Article: Total Return

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.